Country: European Union
Language: English
Source: EMA (European Medicines Agency)
axitinib
Pfizer Europe MA EEIG
L01EK01
axitinib
Protein kinase inhibitors
Carcinoma, Renal Cell
Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.
Revision: 14
Authorised
2012-09-03
45 B. PACKAGE LEAFLET 46 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT INLYTA 1 MG FILM-COATED TABLETS INLYTA 3 MG FILM-COATED TABLETS INLYTA 5 MG FILM-COATED TABLETS INLYTA 7 MG FILM-COATED TABLETS axitinib READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Inlyta is and what it is used for 2. What you need to know before you take Inlyta 3. How to take Inlyta 4. Possible side effects 5. How to store Inlyta 6. Contents of the pack and other information 1. WHAT INLYTA IS AND WHAT IT IS USED FOR Inlyta is a medicine containing the active substance axitinib. Axitinib reduces the blood supply to the tumour and slows down the growth of cancer. Inlyta is indicated for the treatment of advanced kidney cancer (advanced renal cell carcinoma) in adults, when another medicine (called sunitinib or a cytokine) is no longer stopping disease from progressing. If you have any questions about how this medicine works or why this medicine has been prescribed for you, ask your doctor. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE INLYTA DO NOT TAKE INLYTA: If you are allergic to axitinib or any of the other ingredients of this medicine (listed in section 6). If you think you may be allergic, ask your doctor for advice. WARNINGS AND PRECAUTIONS TALK TO YOUR DOCTOR OR NURSE BEFORE TAKING INLYTA • IF YOU HAVE HIGH BLOOD PRESSURE. Inlyta can raise your blood pressure. It is important to check your blood pressure before you take this medicine, and regularly while you are taking it. If you have high blood pressure Read the complete document
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Inlyta 1 mg film-coated tablets Inlyta 3 mg film-coated tablets Inlyta 5 mg film-coated tablets Inlyta 7 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Inlyta 1 mg film-coated tablets Each film-coated tablet contains 1 mg of axitinib. _ _ Inlyta 3 mg film-coated tablets Each film-coated tablet contains 3 mg of axitinib. Inlyta 5 mg film-coated tablets Each film-coated tablet contains 5 mg of axitinib. Inlyta 7 mg film-coated tablets Each film-coated tablet contains 7 mg of axitinib. _ _ Excipients with known effect _Inlyta 1 mg film-coated tablet _ Each film-coated tablet contains 33.6 mg of lactose monohydrate. _Inlyta 3 mg film-coated tablet_ Each film-coated tablet contains 35.3 mg of lactose monohydrate. _Inlyta 5 mg film-coated tablet _ Each film-coated tablet contains 58.8 mg of lactose monohydrate. _Inlyta 7 mg film-coated tablet _ Each film-coated tablet contains 82.3 mg of lactose monohydrate. _ _ For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet). Inlyta 1 mg film-coated tablets Red oval film-coated tablet debossed with “Pfizer” on one side and “1 XNB” on the other. Inlyta 3 mg film-coated tablets Red round film-coated tablet debossed with “Pfizer” on one side and “3 XNB” on the other. Inlyta 5 mg film-coated tablets Red triangular film-coated tablet debossed with “Pfizer” on one side and “5 XNB” on the other. Inlyta 7 mg film-coated tablets Red diamond shaped film-coated tablet debossed with “Pfizer” on one side and “7 XNB” on the other. 3 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _ _ Treatment with Inlyta should be conducted by a physician experienced in the use of anticancer therapies. Posology _ _ The recommended Read the complete document